Alnylam Pharmaceuticals
ALNY
#644
Rank
โ‚น2.754 T
Marketcap
โ‚น21,280
Share price
-1.30%
Change (1 day)
71.19%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น359.13. In 2022 the company made an earnings per share (EPS) of -โ‚น811.76 a decrease over its 2021 EPS that were of -โ‚น629.14.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-58.46%
2022-โ‚น811.7629.03%
2021-โ‚น629.14-3.36%
2020-โ‚น650.98-8.48%
2019-โ‚น711.277.67%
2018-โ‚น660.5939.74%
2017-โ‚น472.7312.94%
2016-โ‚น418.5538.84%
2015-โ‚น301.46-32.88%
2014-โ‚น449.13259.44%
2013-โ‚น124.95-31.25%
2012-โ‚น181.7552.94%
2011-โ‚น118.8430.77%
2010-โ‚น90.88-8.77%
2009-โ‚น99.6178.13%
2008-โ‚น55.92-70.78%
2007-โ‚น191.3699.09%
2006-โ‚น96.12-43.88%
2005-โ‚น171.26-82.33%
2004-โ‚น969.34-59.23%
2003-โ‚น2,378

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น148.55-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,265-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น684.19 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.59-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น147.67-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น326.80-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น277.89-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น174.76-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel